Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.980435
Abstract: Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several… read more here.
Keywords: antibody cocktail; non competing; amubarvimab romlusevimab; sars cov ... See more keywords
Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments.
Sign Up to like & getrecommendations! Published in 2022 at "Drug discoveries & therapeutics"
DOI: 10.5582/ddt.2022.01055
Abstract: The coronavirus disease 2019 (COVID-19) pandemic continues to ravage the world, and the virus' constant evolution has made it increasingly difficult to contain. The combination of the neutralizing antibodies amubarvimab and romlusevimab has recently been… read more here.
Keywords: listing neutralizing; neutralizing antibodies; romlusevimab china; china ... See more keywords